(Q36188935)

12 August 2017

1 reference

title

Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues (English)

1 reference

adaptive radiation therapy

12 August 2017

main subject

0 references

1 reference

Alan M Nichol

1

1 reference

12 August 2017

Padraig Warde

series ordinal

2

1 reference

12 August 2017

Robert G Bristow

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

104

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

891-905

1 reference

The proportion of stem cells in murine tumors

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

Activation of CDK4 gene expression in human breast cancer cells by the Brn-3b POU family transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

National practice patterns and time trends in androgen ablation for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

What defines intermediate-risk prostate cancer? Variability in published prognostic models

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

National Comprehensive Cancer Network guidelines for the management of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Baseline staging of newly diagnosed prostate cancer: a summary of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Prostate cancer radiotherapy dose response: an update of the fox chase experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Correlation of tumor oxygen dynamics with radiation response of the dunning prostate R3327-HI tumor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The hypoxic tumour microenvironment and metastatic progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The p53 protein family and radiation sensitivity: Yes or no?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Delineation of prognostic biomarkers in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Gene expression correlates of clinical prostate cancer behavior

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Gene expression profiling identifies clinically relevant subtypes of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The Gleason score shift: score four and seven years ago.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Gleason grading and prognostic factors in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The Gray Lecture 2001: coming technical advances in radiation oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Time factor and treatment strategies in subclinical disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Re: Vikram, B., The PSA conundrum. Radiother Oncol, 2004. 71(1): p. 1–2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer - a systematic review.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

A systematic overview of radiation therapy effects in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Hazards of dose escalation in prostate cancer radiotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Normal tissue effects: reporting and analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Late effects of radiotherapy: how to assess and improve outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Radical Prostatectomy and Radical Radiation Therapy for Clinical Stages T1 to 2 Adenocarcinoma of the Prostate: New Insights into Outcome from Repeat Biopsy and Prostate Specific Antigen Followup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Lack of prostate cancer radiosensitization by androgen deprivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Pattern of proliferative index (Ki-67) after anti-androgen manipulation reflects the ability of irradiation to control prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Radiation therapy and androgen suppression as treatment for clinically localized prostate cancer: the new standard?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Combination hormonal therapy: a reassessment within advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Pretreatment predictors of time to cancer specific death after prostate specific antigen failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Pion conformal radiation of prostate cancer: results of a randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

What hypofractionated protocols should be tested for prostate cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Targeting tumor cells by enhancing radiation sensitivity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Hallmarks of senescence in carcinogenesis and cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Histone deacetylase inhibitors are potent radiation protectants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Histone deacetylase inhibitors--a new tool to treat cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Targeted histone deacetylase inhibition for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Radiosensitivity with Par-4 expression in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Par-4 for molecular therapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Exploiting tumour hypoxia in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21257

7 January 2021

Identifiers

DOI

10.1002/CNCR.21257

1 reference

12 August 2017

1 reference